SubsidieMeestersSmall molecule heparanase inhibitors as anti-metastatic cancer drugs
The Heparanib project aims to validate heparanase inhibitors as cancer treatments by synthesizing compounds, conducting PK/PD studies, and preparing for commercialization and spin-out.
Projectdetails
Introduction
The Heparanib Proof-of-Concept project aims to establish the feasibility of our unique small molecule heparanase inhibitors as drug candidates for the treatment of metastatic cancers.
Experimental Development
To strengthen our science case (experimental development A) and by building on our in vivo data in mouse models for metastatic breast cancer, lung cancer, and multiple myeloma, we will:
- Design a suitable route of synthesis to prepare sufficient quantities of clinical grade material (A-I).
- Synthesize reference compounds (A-II).
- Perform initial pharmacokinetics/pharmacodynamics (PK/PD) studies (A-III).
Business Development
With the aim to prepare for the establishment of a spin-out biotech company (business development B) to take our leads towards the clinic, we will:
- Strengthen our intellectual property (IP) position (B-IV).
- Perform an extensive analysis of the anti-metastatic cancer drug market (B-V).
- Prepare for commercialization by consolidating the results in an investor-ready business plan to develop and commercialize our anticancer drug candidate (B-VI).
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2023 |
| Einddatum | 30-11-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITEIT LEIDENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of a first-in-class inhibitor of FIH for cancer immunotherapyThe project aims to valorise novel small molecule inhibitors of Factor Inhibiting HIF for lung cancer treatment by clarifying IP, engaging investors, and advancing drug candidate development. | ERC Proof of... | € 150.000 | 2022 | Details |
Targeting Mfrn2 to Inhibit Metastatic CancersThis project aims to evaluate a solute carrier transporter as a drug target to inhibit metastatic growth in breast cancer, utilizing patient samples and mouse models for comprehensive analysis. | ERC Proof of... | € 150.000 | 2023 | Details |
Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomicsThe CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms. | ERC Starting... | € 2.481.640 | 2024 | Details |
Catalysis for Cancer Treatment.Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges. | ERC Synergy ... | € 10.603.994 | 2024 | Details |
Bispecific bi-paratopic antibodies for the treatment of cancerThis project aims to develop novel bispecific antibodies to enhance immune response in NSCLC by targeting dual epitopes, potentially improving treatment outcomes for resistant cancer patients. | ERC Proof of... | € 150.000 | 2025 | Details |
Development of a first-in-class inhibitor of FIH for cancer immunotherapy
The project aims to valorise novel small molecule inhibitors of Factor Inhibiting HIF for lung cancer treatment by clarifying IP, engaging investors, and advancing drug candidate development.
Targeting Mfrn2 to Inhibit Metastatic Cancers
This project aims to evaluate a solute carrier transporter as a drug target to inhibit metastatic growth in breast cancer, utilizing patient samples and mouse models for comprehensive analysis.
Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomics
The CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms.
Catalysis for Cancer Treatment.
Cat4CanCenter aims to develop innovative metal-based catalysts and lipid nanoparticle delivery systems to create effective therapies for glioblastoma, overcoming current treatment challenges.
Bispecific bi-paratopic antibodies for the treatment of cancer
This project aims to develop novel bispecific antibodies to enhance immune response in NSCLC by targeting dual epitopes, potentially improving treatment outcomes for resistant cancer patients.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Activeerbare Anti-Kanker ImmunotherapieHet project onderzoekt de haalbaarheid van een nieuw medicijnconcept door een prototype van een activeerbare BiTE te ontwikkelen en te evalueren op concurrentievermogen met bestaande technologieën. | Mkb-innovati... | € 20.000 | 2020 | Details |
Haalbaarheidsproject ontwikkeling therapie tegen kanker stamcellenHet project onderzoekt de haalbaarheid van het synthetiseren van stoffen die kanker stamcellen remmen, met als doel deze cellen uit te schakelen en een vervolgproject te initiëren. | Mkb-innovati... | € 20.000 | 2020 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Anticancer approach based on the Metabolic Disruption of Cancer Stem Cells with high effectivity across a wide range of solid tumoursThe project aims to develop the novel anticancer agent IGN116, targeting cancer stem cells in CRC and PDAC, to provide effective treatment with low toxicity, benefiting thousands of patients by 2040. | EIC Transition | € 2.498.015 | 2025 | Details |
ONCO IDBIMINI Biotech onderzoekt de haalbaarheid van innovatieve therapieën voor longkanker om de overlevingskansen van patiënten te verbeteren en een impact te maken op de behandeling van kanker. | Mkb-innovati... | € 20.000 | 2021 | Details |
Activeerbare Anti-Kanker Immunotherapie
Het project onderzoekt de haalbaarheid van een nieuw medicijnconcept door een prototype van een activeerbare BiTE te ontwikkelen en te evalueren op concurrentievermogen met bestaande technologieën.
Haalbaarheidsproject ontwikkeling therapie tegen kanker stamcellen
Het project onderzoekt de haalbaarheid van het synthetiseren van stoffen die kanker stamcellen remmen, met als doel deze cellen uit te schakelen en een vervolgproject te initiëren.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
Anticancer approach based on the Metabolic Disruption of Cancer Stem Cells with high effectivity across a wide range of solid tumours
The project aims to develop the novel anticancer agent IGN116, targeting cancer stem cells in CRC and PDAC, to provide effective treatment with low toxicity, benefiting thousands of patients by 2040.
ONCO ID
BIMINI Biotech onderzoekt de haalbaarheid van innovatieve therapieën voor longkanker om de overlevingskansen van patiënten te verbeteren en een impact te maken op de behandeling van kanker.